Abstract
Resting-state fMRI has the potential to find abnormal behavior in brain activity and to diagnose patients with depression. However, resting-state fMRI has a bias depending on the scanner site, which makes it difficult to diagnose depression at a new site. In this paper, we propose methods to improve the performance of the diagnosis of major depressive disorder (MDD) at an independent site by reducing the site bias effects using regression. For this, we used a subgroup of healthy subjects of the independent site to regress out site bias. We further improved the classification performance of patients with depression by focusing on melancholic depressive disorder. Our proposed methods would be useful to apply depression classifiers to subjects at completely new sites.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by AMED under Grant Number JP19dm0107096, and Research on Medical ICT and Artificial Intelligence (H29-ICT-General-010), Health, Labour and Welfare Sciences Research Grants, Ministry of Health, Labour and Welfare Japan.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
The original data for this study is confidential due to the involvement of patient data. It can be obtained upon request to the Department of Psychiatry and Neurosciences, Hiroshima University, Japan (primary contact: Shigeto Yamawaki, PhD, MD, yamawaki@hiroshima-u.ac.jp). IRB imposing these restrictions on our data is Ethical Committee for Epidemiology of Hiroshima University (contact: Shoji Karatsu kasumi-kenkyu@office.hiroshima-u.ac.jp). Additional contact information is available from: https://www.hiroshima-u.ac.jp/en/pharm/contact.
